Product Description
Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25313327/)
Mechanisms of Action: CTSS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| I5U-MC-ANBB | P1 |
Completed |
Healthy Volunteers |
2012-05-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/01/2022 |
PubMed |
Cathepsin S is a novel target for age-related dry eye. |
|
09/19/2021 |
PubMed |
Cathepsin S Evokes PAR2-Dependent Pain in Oral Squamous Cell Carcinoma Patients and Preclinical Mouse Models. |